Vigonvita Life Sciences' 2025 Loss Widens

MT Newswires Live

04/01

Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.

Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.

Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.

Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.

The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.

The company did not declare any dividend for the year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2624569473"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624569473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624569473?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 12:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624569473","market":"nz","top_or_hot":-1,"title":"Vigonvita Life Sciences' 2025 Loss Widens","media":"MT Newswires Live","content":"<html><body><p> Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.</p><p>Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.</p><p>Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.</p><p>Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.</p><p>The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.</p><p>The company did not declare any dividend for the year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences' 2025 Loss Widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences' 2025 Loss Widens\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-01 12:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.</p><p>Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.</p><p>Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.</p><p>Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.</p><p>The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.</p><p>The company did not declare any dividend for the year.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624569473","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624569473","pubTimestamp":1775018812,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vigonvita Life Sciences  booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.The company did not declare any dividend for the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02630":"旺山旺水-B"},"translate_title":"VigonVita Life Sciences 2025年亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.The company did not declare any dividend for the year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}